Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Frequently asked questions
What sector does Phathom Pharmaceuticals, Inc (PHAT) operate in?
Phathom Pharmaceuticals, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Phathom Pharmaceuticals, Inc (PHAT) current stock price?
As of the latest data, Phathom Pharmaceuticals, Inc stock price is $5.94, with a previous close of $5.74. Phathom Pharmaceuticals, Inc gained $0.20 in the last trading session, representing a 3.48% increase.
What is Phathom Pharmaceuticals, Inc (PHAT) current market capitalization?
Phathom Pharmaceuticals, Inc market cap is approximately 480.55 million.
What is Phathom Pharmaceuticals, Inc (PHAT) Earnings Per Share (EPS)?
The trailing EPS is -$1.26, and the forward EPS is $1.08.
What is Phathom Pharmaceuticals, Inc (PHAT) EBITDA?
Phathom Pharmaceuticals, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.37 million.
Does Phathom Pharmaceuticals, Inc (PHAT) pay dividends?
No. Phathom Pharmaceuticals, Inc does not pay a dividend.
How did Phathom Pharmaceuticals, Inc (PHAT) perform in its most recent earnings report?
In the last report (June 30, 2026), Phathom Pharmaceuticals, Inc posted an EPS surprise of 46.67% and a revenue surprise of 2.18%.
When is Phathom Pharmaceuticals, Inc (PHAT) next earnings report?
Phathom Pharmaceuticals, Inc is expected to release its next earnings report on September 30, 2026.
What is Phathom Pharmaceuticals, Inc (PHAT) beta (volatility) score?
Phathom Pharmaceuticals, Inc has a beta of 0.502, indicating lower volatility than the overall market.
